Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
PARP1 as a potential biomarker for response to immunotherapy
In a recent study, the researchers looked at the RNA [...]
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma (RMC)
Renal medullary carcinoma (RMC) is an extremely rare and aggressive [...]
Survival after nephrectomy for various kidney cancer subtypes
Data presented at the American Urological Association (AUA) 2021 meeting [...]
Plan to improve access to GP appointments for NHS patients
Together with the Department of Health and Social Care, NHS [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
One Cancer Voice: Plotting a route out of the pandemic
On Saturday 9 October, the Daily Mail ran a piece [...]
COVID-19: Delay of third jab for extremely vulnerable
Studies have shown that people who are immunosuppressed - around [...]
Cabozantinib in combination with atezolizumab for advanced kidney cancer
This phase Ib study reports the results of a combination [...]
